is anuncommon tutnor tha t usually invo lves a larg e nerve trunk. Only 28 cases of NMC have been previously reported in the Eng lish-Ianguage literature , 17 ofwhich invo lved cranial nerves . We report a new case ofintra cranial N MC that arose fron i a facia lnerve at the cerebellopontine angle in a 44-year-old man. The patient was taken tosurgery, where the lesion was found to invo lve the rightfacialnerve. The tumor was partially removed, and at the 2-yearfollow-up, the patient show ed no sign ofrecurrence.
Introduction
Ne uro musc ular choristoma (NMC)-also ca lled neuromuscular hamartoma/rhabdomyoma or benign triton tlllnor-is an uncommon tumor that usually invo lves a large nerve trunk. Unti l now, only 28 cases ofNMC have been reported in the English-Iang uage literature.':" The first reported case ofNMC, publis hed in 1895 , invo lved the sciatic nerve. ' Since the n, 17 cases of cranial nerve NMC have bee n reported (tab le).6.11 .1 3-1 6The first of these , publis hed in 1989, involved the trigeminal nerve in a chi ld." The second, reported in 1995, involved the facia l nerve ."
Additional cases involving the facia l," cochlear.t-" and optic' " nerves we re subsequently reported. The largest series was reported in 2003 by Wu et al, whose case series included 11 patients seen over a IO-year period."
In this article, we report a new case ofintracranial NMC that arose from a facial nerve. We also review the earlier reports ofintracranial NMCs. 
Case report
A previously healt hy 44-year-old man ca me to us wit h a history of recent-onset progressive hearing loss and tinnitus in the left ear, right epiphora, and mi ld headache. No hearing loss was present in the rig ht ear, and he reported no facia l numbness. On physical examina tio n, he was alert an d spoke fluent ly. The cranial nerves were intact, but he exhibited mi ld fac ial weakness of the lower motor neuron type on the right. Facial sensation was no rma!. Magnetic reso nance imagi ng (M RI) detected an 8-m m enhancing nod ule in the rig ht acoustic meatus (figure I). . The patient was taken to surgery. Intraoperatively, the nod ule was found to intimately invo lve the rig ht fac ial nerve, and it was partially removed. The excised specimen was a 0.5 -cm irregular fragme nt of pink and tan tiss ue. It was fixed in 10% fonnalin and em bedded in paraffin. Histologic sec tio ns were stai ned with hem atoxylin and eosin (H&E). Other special stains incl uded tric hrome and Bielschowsky's si lver. Immunostaining was performed wi th glial fibr illary ac idic pro tein , neurofi lament protein, S-lOO, and the proliferation index MIB-I (Ki -67).
His tologic exa min atio n identified benign striated muscle fibers, most of which were grouped in small fascicles , oriented haphazardly, andseparated by fibro us tissue that conta ined areas of adipose tiss ue an d small nerve fascicles (figure 2, A through D). The muscle fibers were we il developed and featured mu ltip le peripherally located sma ll nuclei, deeply eos inop hi lic cytop lasm, and eas ily discemible cross -striations, No degenerating or regenerating basophi lic muscle fibers were seen, and no nuclear atypia or mitoses were no ted . The muscle fibers were intermixed w ith mye linated nerve fascicles . A sma ll focus of a neuropi l-like structure with rare glial ee lis and corpora amy lacea was located adjacent to the ske letal mu scle (figure 2, C) . The nature of the myelinated ner ve fascicles was we il dem onstrated by trichrome (figure 2, E) and Bie lschowsky's stai ning (figure 2, F), as we il as by immunohistochemica l staining for neurofilament protein (figure 2, G) . No neurons or ganglion ee lis were identified. A few Ki-67-positive eelis were also noted (figure 2, H). The positive nuclei were apparently located in the connective tissue and nerve fibers and were no t associated w ith ske letalmusc le. 
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Discussion
A true triton tumor is a malignant peripheral nerve sheath tumorwith rhabdomyoblastie differentiation, and it is more common than a "benign triton tumor,"17,1 8 In most of the earlier ease reports, the NMC involved a peripheral nerve, often one of a major nerve lIunk. I -S ,7-IO,1 2 Only 3 of these cases oeeurred in adults, and all 3 adults had experieneed neuromuseular symptoms dating baek to ehildhood or adolescence.'?
Intraeranial NMCs oeeur primarily in the aeoustie eanal and eerebellopontine angle , and l Softhe 18reported cases (including ours) involved the vestibuloeoehlear or faeial nerves. Two exceptions were tumors of the trigerninal'' and optic'" nerves; in I case," the exaet loeation was unreported. While extraeranial NMCs are more common in ehiidren, 16 ofthe 18cases ofintraeranial NMCs oeeurred in adults.
Histologieally, the reported cases of intraeranial NMC were similar. These tumors were made up ofan admixture ofbenign, mature elements ofneural, museular, vaseular, and adipose tissue in various proportions. The exaet histogenesis ofNMC is unknown, but Markel and Enzinger postulated that it originates as a hamartomatous malformation seeondary to a eombination of different mature tissue elements. ' In nonnai eireumstanees, no skeletal muscle or adipose tissue is present in the eranium. But the most distinetive histologie feature of intraeranial NMCs is the well-fonned, mature skeletal muscle with various amounts of conneelive tissue and nerve fibers , Another hypothesis regarding the histogenesis of intraeranial NMCs is that eranial nerves trap skeletal muscle during embryogenesis," Aeeording to other theories, neuroeetodenn differentiates toward mesenchyme.":"
Regarding the neoplastie potential ofNMCs, Mitchell et al reported that they had found proliferative index marker Ki-67 aet ivity in an NMC lesion , and they suggested that it is a slow-growing neoplasm." They preferred to eall this lesion a rhabdomyoma ofthe adult type . Their theory was supported by the faet that several patients with NMC experieneed multiple reeurrenees following reseetion.4,8,10. 1 2 On the other hand , Louhimo and Rapola reported 2 cases ofNMCs that underwent spontaneous regression following biopsy and subtotal resection.' They did not reportwhether
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The followingtreatment-relatedadverseeventswere each reportedIn a sinqla patient: tym panostomytube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizziness: and erythema. Aeut e Otitis Externa: The following treatment-related adve rseevents occurredin0.4% or mare of the patients withintaettympaniemembranes.
Pregnancy
Teratogenic Effects. Pregnaney Category C: Reproduction studies have been performedin rats and mice using oral doses of upto 100 mg/kg and IVdosesup to 30mg/kg andhave revealed no evideneeof harmto the fetus as a result of eiprotloxaein. ln rabbits, eiprotloxae in (3D and 100mg/kg orallyl produeed gastrointestinal disturbanees resulting in maternaI weig ht loss and an increased incidenceofabortian, butnoteratogenici ty wasobserved at either dose. After intravenous administ ration of doses up to 20mg/kg, no maternai toxic itywas produced in the rabbit, and no embryotoxicityor teratoge nicitywasobserved. Corticostero ids aregenerally teratogenie in laboratorvani malswhen administeredsystemieallyat relatively low dosage leveIs. The more patenteorticosteroidshave been showntobeteratogenie after dermaI applicationinlaboratoryanimaIs. Animal reproduction studies have not been eonduetedwith CIPRO OEX' Otic. No adequateandweil eontrolledstudieshave beenperformed in pregnant women. Cauti on should beexereisedwhen CIPRDOEX' Ot ie is used bya pregnantwoman. Nursing Mothers: Ci profloxacin and corticosterolds, as a class, appear in rnilk foll owing araI administration. Dexamethasone in breast rnilkeould suppress growth, interfere with endogenous corticosteroid produetion, or causeother untoward eHects. It is not known whether topieal otic administratio n ofciprofloxacin or daxamethasone could result in sufticient systemic absorption to producedeteetable quantitles in human milk, Because of thepotential forunwanted eHects in nursingintants. a decisionshould be made whether to disconti nue nursing or to diseontinuethe drug, taking into aeeount theimportanee of the drugto thernother; Pediatrie Use: The safety and eHieaeyof CIPROOEX' Dtie have been establishedin pediatrie patients 6 months andolder (937patients) in adequateand well-eontrolled elinieal trials. Althoughno dara are available onpatients lessthanage6 months, there are no known satetv concernsordiff erencesinthedisease process inthispopulation that would preel ude use of this produet. (See DOSAGE AND ADMINISTRATION.} No elinieally relevant ehangesin hearing funetion were observed in 69 pediatrie patients (age 4 to 12 years) treatedwith CIPROOEX'
Otie andtested for audiomet ricparameters.
ADVERSE REACTIONS
In Phases II and III e1inieal trials, a tatal of 937 patients were treated with CIPRD OEX' Otie. This ineluded 400 patientswith aeute otitismediawith tympanostomy tubes and537 patients with aeute otitis axtsrna. The reported treatrnent-related adve rseeventsarelisted below: Aeute Dtitis Media in pediatrie patients with tympanostomy tubes: The followi ng treatment-related adverse events occurredin0.5% Drmare of the patients with non-inteet tympa nic membranes. HOW SUPPLlEO . CIPRO OEX'(eiprofl oxaein 0.3% and dexamethasone0.1 %1Steriie Otie Suspension is supplied asfollows:5 mLfill and7.5mLfill ina OR OP-TAINER' system.The OR OP-TAINER ' systemeonsists of a naturalpolyet hylenebottleand natural plug,with awhite pol ypropylene elosure. Tamper evideneeis provided with a shrinkband around theelosure and neek areaof the paekage. NOC 0065-8533-01, 5 mL fill; NOC 0065-8533-02, 7.5 mLfill. Storage: Store at eontrolled roomtemperature, 15' Cto 30'C(59'F to 86'F). Avoid freezing. Proteet fromlight. Clinieal Studies: In a randomized, mul ticenter, eontrolledelinieal trial, CIPR OOEX' Otie dosed 2times per day for 7 days demonstrated e1inieal eures in the per protoeal analysisin 86%of AOMT patients eompared to 79% for ofloxacin solutian,0.3%, dosed 2 times per day for 10days. Amo ng culture positive patients, clinical cureswere 90%for CIPRDOEX' Oti e eompared to79%for otloxaei nsolution,0.3%. Mierobi ologieal eradieation rates forth ese patientsinthesamee1inieal trial were91%for CIPROOEX' Oti e eompared to 82%for otloxaein solution, 0.3%. In 2 randomized multicenter, eontrolled elinieal trials, CIPROOEX' Otie dosed 2times per day for 7 days demonstrated elinieal eures in 87%and 94%of per protoeal evaluable AOE patient s, respeetivel y, eompared to 84% and89%, respeetively, for otie suspension containing neomyein 0.35%, polymyxin B 10,000 IUimL, and hydroeortisone 1.0% (neo/poly/HC). Amongculture positive pati ents elinieal eureswere 86%and 92%for CIPROO EX' Otie eomparedto 84%and89%, respeetivel y, for neo/poly/HC.Mierobiologieal eradieation rates for these patientsinthesameelinieal trials were 86% and92%for CIPRDOEX' Dtie eomparedto 85%and85%, respeetively, for neo/poly/HC. for adjust mentof pH. Ciprofloxaein, a fluoroquinolone is avai lable asthemonohydroehloridemonohydrate sal t of 1-eyelopropyl-6-fluoro-1,4-dihydro-4-oxo+ (1 -piperazinyll-3-quinolineearboxylie acid. The empirieal formula is C17H 18FN303-H CI ·H20. Oexamethasone, 9-tluoro-l1(beta}, 17 ,21-trihydroxy-16(alphal-methylpregna-l ,4-diene-3,20-dione, is an antiinflammatoryeortieoste roid. The empiriealformul a is C22H29F0 5.
Alcari
CUNICAL PHARMACOLOGV
Pbarmaeokineties: Following a single bilateral 4-drop (total dose = 0.28 mL, 0.84 mg eiprofloxaein, 0.28 mgdexamet hasonel topieal otic dose of CIPRO DEX!!Otic to pediatric patients after tympa nos tomy tube insertio n,rneasurable plasmaconcentrations of ciprolloxacin anddexamethasonewere observed at 6 hours foll owing administrationin 2 of 9 patientsand 5of 9 patients, respeetively. Mean± SOpeakplasmaeoneentrations of eiprofloxaein were 1. 39± 0.880 ng/mL(n=91. Peakplasma eoneent rations ranged from0.543 ng/mLto3.45ng/mLandwere onaverage approximately 0.1 %of peak plasma eoneentrations achieved with an oraldose of250-mg 1 31 . Peak plasma concentrationsat ciprofloxacin wereobserved within 15 minutesto2hourspost dose application. Mean± SOpeak plasma concentrations of dexamethasone were 1.14 ± 1. 54ng/mL(n=9). Peak plasmaeoneentrations ranged from 0.135 ng/mL to 5.10ng/mL and were on average approximately 14% of peakeoneentrations reported in the literature following an oral 0.5-mg tablet dose". Peak plasma concentrations of dexamet hasone were observed within15mi nutes to 2 hou rs post dose app lication. Dexamethasone has been added to aid in the resolution of the inflammatory responseaccompa nying bacterial infeetion(such as otorrhea in pediatrie patients with AOMwith tympanostomytubes). Microbiology: Ci profloxacin has in vitro activity against a wide range of qrarn-positive and gram-negative microorganisms. The bactericidal action of ciprofJoxa cinresultsfrominterferenee with the enzyme, DNA gyrase, whieh is needed for the synthesis of baeterial ONA. Cross-resistanee has been observed between eiprofloxaein andother fluoroquinolones. There is generaHv no cross-resistance between ciprofloxacin and other elasses of antibacterial agentssuch asbeta -lactarns or ami noglycosides. 
PRECAUTIONS
General: Aswithother antibacterial prepa rations,use at this product may resultin ove rgrowt h of nonsusceptible organi sms, inel uding yeast andfun gi. Ittheinfection is not improvedafter oneweek of treatment , cultures should be abtained toguidefurt hertreatment If otorrheapersists after a full courseof therapy, or iftwoormare episodes of otorrhea occur withi n sixmonths, further evaluation is recommended to excludean underlyingcondition such ascholesteato ma, foreignbody, or a tum or. The systemic administ ration ofquinclones, includin g ciprofloxaci n at doses much higher thangiven or absorbed bythe otic route, has led to lesions or erosions of the cartilage in weight-bearing jointsand oth er signsof arthropathyinimmatur e ani malsof various species. Guinea pigsdosed in the middle ear with CIPRODEX' Otie for one month exhibitedno drug-related struetural or funetional ehangesof thecochlear hair cells and nolesions inthe ossieles. CIPRODEX&Otic wasalsoshown to lack dermaI sensitizi ng potential inthe guineapig whentested aeeordingto themethodof Buehler. No signsol laeal irritation werefound when CIPRDOEX' Otie was applied topieally in the rabbit eVe. Information for Patients: For otie use only. (Thi s product is not app roved tor use in the eye.) Warmthe bottle inyour hand for onetotwominutes pri orto use and shake weil immediately before using. Avo id conta minating the tip with material from the ear, tingers, or other Fertility studies performed in rats at oral doses of eiprofloxaei n up to 100 mg/kg/day revealed no evidenee of impairment This would be over 100 times the maximumreeommended elinic al dose of ototopical ciprofJoxacin based uponbody surfaee area,assu mi ngtotal absorption of ciprofJoxacinfrom the ear of a patient treated with C I P ROD EX~Otie twiceper day acco rdingto labei directions. Long term studies have notbeen performed to evaluatethecarcinogeni c pote ntial oftopical otic dexamethasone. Oexamethasone has been tested for invitro andinvivo genotoxic potential and shown to be posit ive inthe following assays; chromosomal aberrations, sister·ehromatid exchange in hum an Iymphocytes and micronuel ei and sister·chromatid exehanges in mouse bone marrow. However, the Ames/Salmonell a assay, both with andwithout S9mix, didnot showanyincrease in His+ revertants. The effect of dexamethasoneonfertilityhasnot been investigated foll owing topicalotic application. However, the lowest toxic doseof dexamethasoneidentifiedfollowing topieal dermai appl ieation was1.802mg/kg in a 26-week studyinmale rats andresultedin changestothetestes, epididymis, spermduct , prostate, semi nal vessicle. Cowpers glandand aeeessory glands. The relevance ofthisstudyfor shortterm topieal otie use isunknown.
